|
1
|
Watkins EJ: Overview of breast cancer.
JAAPA. 32:13–17. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Xia C, Dong X, Li H, Cao M, Sun D, He S,
Yang F, Yan X, Zhang S, Li N and Chen W: Cancer statistics in China
and United States, 2022: Profiles, trends, and determinants. Chin
Med J (Engl). 135:584–590. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Peddi PF and Slamon DJ: Frontiers in
HER2-positive breast cancer in 2020. Curr Opin Obstet Gynecol.
33:48–52. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Goutsouliak K, Veeraraghavan J, Sethunath
V, De Angelis C, Osborne CK, Rimawi MF and Schiff R: Towards
personalized treatment for early stage HER2-positive breast cancer.
Nat Rev Clin Oncol. 17:233–250. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Takada M and Toi M: Neoadjuvant treatment
for HER2-positive breast cancer. Chin Clin Oncol. 9:322020.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Cesca MG, Vian L, Cristóvão-Ferreira S,
Pondé N and de Azambuja E: HER2-positive advanced breast cancer
treatment in 2020. Cancer Treat Rev. 88:1020332020. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Korde LA, Somerfield MR, Carey LA, Crews
JR, Denduluri N, Hwang ES, Khan SA, Loibl S, Morris EA, Perez A, et
al: Neoadjuvant chemotherapy, endocrine therapy, and targeted
therapy for breast cancer: ASCO guideline. J Clin Oncol.
39:1485–1505. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hurvitz SA, Martin M, Symmans WF, Jung KH,
Huang CS, Thompson AM, Harbeck N, Valero V, Stroyakovskiy D,
Wildiers H, et al: Neoadjuvant trastuzumab, pertuzumab, and
chemotherapy versus trastuzumab emtansine plus pertuzumab in
patients with HER2-positive breast cancer (KRISTINE): A randomised,
open-label, multicentre, phase 3 trial. Lancet Oncol. 19:115–126.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wang H, Li Y, Qi Y, Zhao E, Kong X, Yang
C, Yang Q, Zhang C, Liu Y and Song Z: Pegylated liposomal
doxorubicin, docetaxel, and trastuzumab as neoadjuvant treatment
for HER2-positive breast cancer patients: A phase II and biomarker
study. Front Oncol. 12:9094262022. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Dang C, Ewer MS, Delaloge S, Ferrero JM,
Colomer R, de la Cruz-Merino L, Werner TL, Dadswell K, Verrill M,
Eiger D, et al: BERENICE final analysis: Cardiac safety study of
neoadjuvant pertuzumab, trastuzumab, and chemotherapy followed by
adjuvant pertuzumab and trastuzumab in HER2-positive early breast
cancer. Cancers (Basel). 14:25962022. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Blair HA: Pyrotinib: First global
approval. Drugs. 78:1751–1755. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Xuhong JC, Qi XW, Zhang Y and Jiang J:
Mechanism, safety and efficacy of three tyrosine kinase inhibitors
lapatinib, neratinib and pyrotinib in HER2-positive breast cancer.
Am J Cancer Res. 9:2103–2119. 2019.PubMed/NCBI
|
|
13
|
Li C, Bian X, Liu Z, Wang X, Song X, Zhao
W, Liu Y and Yu Z: Effectiveness and safety of pyrotinib-based
therapy in patients with HER2-positive metastatic breast cancer: A
real-world retrospective study. Cancer Med. 10:8352–8364. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Xu B, Yan M, Ma F, Hu X, Feng J, Ouyang Q,
Tong Z, Li H, Zhang Q, Sun T, et al: Pyrotinib plus capecitabine
versus lapatinib plus capecitabine for the treatment of
HER2-positive metastatic breast cancer (PHOEBE): A multicentre,
open-label, randomised, controlled, phase 3 trial. Lancet Oncol.
22:351–360. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yao DS, Wang W, Chang JY, Zhang Y, Zhang
HW, Xu JX and Cai HF: Neoadjuvant pyrotinib plus nab-paclitaxel,
doxorubicin, and cyclophosphamide for HER2-positive locally
advanced breast cancer: A retrospective case-series study. Gland
Surg. 10:3362–3368. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Xuhong J, Qi X, Tang P, Fan L, Chen L,
Zhang F, Tan X, Yan W, Zhong L, He C, et al: Neoadjuvant pyrotinib
plus trastuzumab and chemotherapy for stage I–III HER2-positive
breast cancer: A phase II clinical trial. oncologist.
25:e1909–e1920. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Tian C, Wang M, Liu H, Liu J, Xu M and Ma
L: Efficacy and safety of neoadjuvant pyrotinib plus
docetaxel/liposomal doxorubicin/cyclophosphamide for HER2-positive
breast cancer. Ir J Med Sci. Jul 13–2022.(Epub ahead of print).
|
|
18
|
Liu Z, Wang C, Chen X, Zhu J, Sun X, Xia
Q, Lu Z, Qiao J, Zhou Y, Wang H, et al: Pathological response and
predictive role of tumour-infiltrating lymphocytes in HER2-positive
early breast cancer treated with neoadjuvant pyrotinib plus
trastuzumab and chemotherapy (Panphila): A multicentre phase 2
trial. Eur J Cancer. 165:157–168. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Cserni G, Chmielik E, Cserni B and Tot T:
The new TNM-based staging of breast cancer. Virchows Arch.
472:697–703. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Litière S, Collette S, de Vries EG,
Seymour L and Bogaerts J: RECIST-learning from the past to build
the future. Nat Rev Clin Oncol. 14:187–192. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhong X, He P, Chen J, Yan X, Wei B, Zhang
Z, Bu H, Li J, Tian T, Lv Q, et al: Neoadjuvant pyrotinib plus
trastuzumab and nab-paclitaxel for HER2-positive early or locally
advanced breast cancer: An exploratory phase II trial. Gland Surg.
11:216–225. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhang L, Wu X, Zhou J, Zhu M, Yu H, Zhang
Y, Zhao Y, Han Z, Guo Y, Guan X, et al: Pyrotinib in the treatment
of women with HER2-positive advanced breast cancer: A multicenter,
prospective, real-world study. Front Oncol. 11:6993232021.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wang C, Deng S, Chen J, Xu X, Hu X, Kong
D, Liang G, Yuan X, Li Y and Wang X: The synergistic effects of
pyrotinib combined with adriamycin on HER2-positive breast cancer.
Front Oncol. 11:6164432021. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Chang J, Xu M, Wang C, Huang D, Zhang Z,
Chen Z, Zhu X and Li W: Dual HER2 targeted therapy with pyrotinib
and trastuzumab in refractory HER2 positive metastatic colorectal
cancer: A result from HER2-FUSCC-G study. Clin Colorectal Cancer.
21:347–353. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Pop L, Suciu ID, Ionescu O, Ionescu P and
Toader OD: The dual blockade in the neoadjuvant setting of HER-2
positive early-stage breast cancer. J Med Life. 12:329–331. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ahn S, Woo JW, Lee K and Park SY: HER2
status in breast cancer: Changes in guidelines and complicating
factors for interpretation. J Pathol Transl Med. 54:34–44. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Mao X, Lv P, Gong Y, Wu X, Tang P, Wang S,
Zhang D, You W, Wang O, Zhou J, et al: Pyrotinib-containing
neoadjuvant therapy in patients with HER2-positive breast cancer: A
multicenter retrospective analysis. Front Oncol. 12:8555122022.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Li Q, Wang Y, Zhu M, Gu Y and Tang Y:
Clinical observation of neoadjuvant chemotherapy with pyrotinib
plus trastuzumab in HER2-positive breast cancer: A cohort study.
Gland Surg. 10:3389–3402. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Bowen JM: Mechanisms of TKI-induced
diarrhea in cancer patients. Curr Opin Support Palliat Care.
7:162–167. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Duan T, Cil O, Thiagarajah JR and Verkman
AS: Intestinal epithelial potassium channels and CFTR chloride
channels activated in ErbB tyrosine kinase inhibitor diarrhea. JCI
Insight. 4:e1264442019. View Article : Google Scholar : PubMed/NCBI
|
